Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Calling it a “historic first,” FDA chief Marty Makary ordered every review decision at the agency to start using a new ...

VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Advanced Solid Tumors To supplement Verastem Oncology’s condensed consolidated financial statements, which are prepared and presented in ...

The partnership builds on the success of Verastem’s Phase 2 RAMP-201 clinical trial, which led to the U.S. Food and Drug Administration’s accelerated approval of a combination therapy for KRAS ...

On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for ...

The Needham, Massachusetts-based company said it had a loss of 96 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

NEEDHAM, Mass. (AP) — NEEDHAM, Mass. (AP) — Verastem Inc. (VSTM) on Tuesday reported a loss of $52.1 million in its first quarter. The Needham, Massachusetts-based company said it had a loss ...